



Repurposing Existing Drugs - Systematic Approaches

05 Aug 2021 - 06 Aug 2021

CONFERENCE PROGRAMME

Thursday, 5th August 2021

13:00	Test Run and Web Checks
13:30	Pre-forum Workshop: Portfolio Enhancement & Product Rationalization (Dr Avijit Kelkar, Co-Founder, AharavConsultants, UK)
14:30	Welcome Address and Introduction to Experts and Expert Forum Sanjay Bajaj , CEO & MD , Glostem Private Limited , India
14:45	Pharmacological & Clinical Aspects in Drug Repurposing Ambrish Srivastava , Clinical Consultant , Evolve Life Research , India
15:15	The Myths of Repurposing Drugs Ken V Phelps , President & Founder , Camargo Pharmaceutical Services , USA
15:45	Drug Repurposing in Oncology - From Candidate Selection to Clinical Investigation Pan Pantziarka , Programme Director - Drug Repurposing , Anticancer Fund , United Kingdom
16:15	Open Discussion/Rap Session: (Experts - Purushottam Dewang and Pratima Srivastava)
16:35	Regulatory Pathways for Repurposed Drugs and 505(B)2 Hurdles Asoke Mukherjee , Former - Senior Expert Pharmacologist , FDA , USA
17:05	Reverse Pharmacology and Systems Approaches for Chemical Biology, Drug Discovery and Development: Inspiration from the Wisdom of Mother Nature Mukund Chorghade , President and Chief Scientific Officer , THINQ Pharma , USA
17:35	End of First Day of meeting

Friday, 6th August 2021

14:30	Recap of Day 1 and Introduction to Day 2 Experts Sanjay Bajaj , CEO & MD , Glostem Private Limited , India
14:40	Repositioning of Existing Drugs through Novel Product Development Approaches Rakesh Bhasin , Vice President - Gen-Form , Biocon Limited , India
15:10	Open Discussion - Formulation Development Approaches (Lead Experts - Manish Grover and WantaneePhuapradit)

15:29	Drug Repurposing using In Silico and 3D Human Vascular Lung Models: A Case Example for Covid Antiviral Clinical Candidate Selection
15:30	Overview of Drug Repurposing for Covid Antiviral Clinical Candidate Subrahmanyam Vangala , CEO & Co founder , ReaGene Biosciences Pvt Ltd, India (Keynote Speaker) , India
15:45	In Silico Screening of 8000 FDA Drugs for SARS-Cov-2 Antiviral Activity Sreedhara R Voleti , Founder-MD/CEO , INDRAS Pvt. Ltd , India
16:05	3D Human Vascular Lung Model for Clinical Validation for Drug Repurposing as SARS-Cov-2 Antiviral Drugs Uday Saxena , Co-Founder , Reagene Biosciences , India
16:25	Q/A Session
16:45	Open Discussion - (Expert - Dr Purushottam Dewang)
17:15	Networking in Forum Lounge
17:30	Closing Remarks and End of the meeting